Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
2,457 results
  • A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. [Journal Article]
    Am J Drug Alcohol Abuse 2019; :1-8Sibai M, Mishlen K, … Bisaga A
  • CONCLUSIONS: The results support the feasibility of a week-long outpatient induction onto XR-naltrexone with ascending doses of naltrexone and standing doses of adjunctive medications. By circumventing the need for a protracted period of abstinence and mitigating the severity of withdrawal symptoms experienced during naltrexone titration, this strategy has the potential to increase patient acceptability and access to relapse prevention treatment with XR-naltrexone.
  • Efficacy of SM-1 in a transient insomnia model. [Journal Article]
    Hum Psychopharmacol 2019; 34(6):e2713Dahl T, Chen LB, … Roth T
  • CONCLUSIONS: SM-1 provided a robust and statistically significant increase in TST compared with placebo in a circadian model of transient insomnia, without evidence of next-day impairment. Diphenhydramine contributed to the effect.
  • Zolpidem-Associated Consequences: An Updated Literature Review With Case Reports. [Journal Article]
    J Nerv Ment Dis 2020; 208(1):28-32Westermeyer J, Carr TM
  • A post-2000 literature search reviewed prevalence of health consequences associated with zolpidem, plus two salient case reports. Common zolpidem-related harms encompassed accidents, falls, overdoses, delirium, and infections. Risks to others included assaults, vehicular accidents, various crimes, and civil actions that occurred during zolpidem-induced delirium, withdrawal, and other impediments.…
  • Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. [Journal Article]
    Arch Pharm Res 2019; 42(12):1101-1106Lee CM, Jung EH, … Lee SY
  • Zolpidem is extensively metabolized by CYP3A4, CYP2C9 and CYP1A2. Previous studies demonstrated that pharmacokinetics of zolpidem was affected by CYP inhibitors, but not by short-term treatment of clarithromycin. The objective of this study was to investigate the effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. In the control phase, 33 subjects recei…
New Search Next